Efficacy and safety of almotriptan malate for migraine

American Journal of Health-System Pharmacy

Volumn 59, Issue 22, 2002, Pages 2184-2193

  Balbisi, Ebrahim A ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Almotriptan malate; Contraindications; Costs; Dosage; Drugs availability; Half life; Migraine; Pharmacokinetics; Serotonin agonists; Toxicity

Indexed keywords

ALMOTRIPTAN; ERYTHROMYCIN; FLUOXETINE; KETOCONAZOLE; MOCLOBEMIDE; NARATRIPTAN; PLACEBO; RIFAMPICIN; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN SUCCINATE; VERAPAMIL; ZOLMITRIPTAN;

ATRIOVENTRICULAR BLOCK; BACKACHE; BRONCHITIS; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY SPASM; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEALTH CARE COST; HEART PALPITATION; HUMAN; HYPERTENSION; HYPESTHESIA; ISCHEMIC HEART DISEASE; LEG PAIN; MIGRAINE; NAUSEA; NYSTAGMUS; PARESTHESIA; PATHOLOGICAL REFLEX; PATIENT SATISFACTION; PHOTOPHOBIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0037111781     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.22.2184     Document Type: Review

References (48)

1. Lipton RB, Stewart WF, Diamond S et al. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001; 41:646-57.
2. Marks DR, Rapoport AM. Diagnosis of migraine. Semin Neurol. 1997; 17:303-6.
3. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attack therapies. Brain. 1994; 117:427-34.
4. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 1993; 43(6, suppl 3):S16-20.
5. Raskin NH. Migraine and other headaches. In: Rowland LP, ed. Merritt's Neurology. 10th Ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 807-13.
6. Lipton RB, Stewart WF. Migraine in the United States: A review of epidemiology and health care use. Neurology. 1993; 43(6, suppl 3):S6-10.
7. Hu XH, Markson LE, Lipton RB et al. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999; 159:813-8.
8. Nappi G, Agnoli A, Manzoni GC et al. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalagia. 1988; 8(suppl 7):1-96.
9. Mulleners WM, Aurora SK, Chronicle EP et al. Self-reported photophobic symptoms in migraineurs and controls are reliable and predict diagnostic category accurately. Headache. 2001; 41 (1):31-9.
10. Russell MB, Rasmussen BK, Fenger K et al. Migraine without aura and migraine with aura are distinct clinical entities: A study of four hundred and eighty-four male and female migraineurs from the general population. Cephalagia. 1996; 16(4):239-45.
11. Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clin Proc. 1996; 71:1055-66.
12. Goadsby PJ. Serotonin receptors and the acute attack of migraine. Clin Neurosci. 1998; 5(1):18-23.
13. IB/ID receptor: A central action in migraine? Ann Neurol. 1998; 43:711-8.
14. Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs. 1998; 55:889-922.
15. Axert (Almotriptan Malate) Package Insert. Chicago: Pharmacia; 2001.
16. Bou J, Domenech T, Puig J et al. Pharmacological characterization of almotriptan: An indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol. 2000; 410:33-41.
17. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000; 60:1259-87.
18. ID alpha serotonin receptor gene expression in trigeminal ganglia: Implications for antimigraine drug development. Proc Natl Acad Sci U S A, 1994; 91:3666-9.
19. Cabarrocas X, Salva M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. Cephalagia. 1997; 17:421. Abstract.
20. Robert M, Warrington SJ, Zayas JM et al. Electrocardiographic effects and pharmacokinetics of oral almotriptan in healthy subjects. Cephalagia. 1998; 18: 406. Abstract.
21. Fernandez FJ, Jansat JM Cabarrocas X et al. Absolute bioavailability of oral and subcutaneous almotriptan. Cephalagia. 1999; 19:363. Abstract.
22. IB/ID receptor agonists in migraine. Comparative pharmacology and its therapeutic implications. CNS Drugs. 1998; 10(4):271-86.
23. Holm KJ, Spencer CM. Almotriptan. CNS Drugs. 1999; 11(2):159-64.
24. Deleu D, Hanssens Y. Current and emerging second-generation triptans in acute migraine therapy: A comparative review. J Clin Pharmacol. 2000; 40:687-700.
25. Palacios JM, Rabasseda X, Castaner J. Almotriptan. Drugs Fut. 1999; 24:367-74.
26. IB/ID agonist, in healthy volunteers. Headache. 1998; 38:381. Abstract.
27. Cabarrocas X, Fernandez FG, Popescu G et al. The pharmacokinetics and tolerability of almotriptan in renal impairment. Headache. 1999; 39:346. Abstract.
28. Pascual J, Falk R, Docekal R et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol. 2001; 45:206-13.
29. Cabarrocas X, Esbri R, Peris F et al. Long-term efficacy and safety of oral almotriptan: Interim analysis of a 1-year open study. Headache. 2001; 41:57-62.
30. Pascual J, Falk RM, Piessens F et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebocontrolled study. Cephalagia. 2000; 20:588-96.
31. Dahlof C, Tfelt-Hansen P, Massiou H et al. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology. 2001; 57:1811-7.
32. Spierings EL, Gomez-Mancilla B, Grosz DE et al. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol. 2001; 58:944-50.
33. Colman SS, Brod MI, Krishnamurthy A et al. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther. 2001; 23:127-45.
34. Hartmaier SL, Santanello NC, Epstein RS et al. Development of a brief 24-hour migraine-specific quality of life questionnaire. Headache. 1995; 35:320-9.
35. Boyce M, Dunn K, Warrington S. Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. J Cardiovasc Pharmacol. 2001; 37:280-9.
36. Fleishaker JC, Sisson TA, Carel BJ et al. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalagia. 2001; 21:61-5.
37. Fleishaker JC, Ryan KK, Jansat JM et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol. 2001; 51:437-41.
38. Fleishaker JC, Sisson TA, Carel BJ et al. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther. 2000; 67:498-503.
39. Fleishaker JC, Ryan KK, Carel BJ et al. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol. 2001; 41:217-23.
40. Mayo KW, Osterhaus JT. Health outcomes evaluations: Estimating the impact of almotriptan in managed care settings. Am J Manag Care. 2002; 8(suppl 3):85-93.
41. Wang JT, Barr CE, Torigoe Y et al. Cost savings in migraine associated with less chest pain on new triptan therapy. Am J Manag Care. 2002; 8(suppl 3):102-7.
42. Rothermich EA, Levaux HP, Colman SC et al. Cost minimization analysis of almotriptan versus sumatriptan for the acute treatment of a moderate to severe migraine headache. Int Pharm Abst. 2000; 37:2311. Abstract.
43. Red Book. Montvale, NJ: Medical Economics; 2002.
44. IB/ID agonists. Arch Intern Med. 2001; 161:2545-53.
45. Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: A review of its use in migraine. Drugs. 1999; 58:347-74.
46. Dooley M, Faulds D. Rizatriptan: A review of its efficacy in the management of migraine. Drugs. 1999; 58:699-723.
47. Gruffyd-Jones K, Kies B, Middleton A et al. Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: A randomized, double-blind, international study. Eur J Neurol. 2001; 8:237-45.
48. Goldstein J, Ryan R, Jiang K et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan protocol 046 study group. Headache. 1998; 38:737-47.